Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033 Life Science Investing
KORU Medical Systems Announces Development Agreement for Innovation in Subcutaneous Immunoglobulin Infusion Systems Life Science Investing
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update Life Science Investing
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Medical Device Investing
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 Life Science Investing
Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit Life Science Investing
